Immunomedics Inc. (NASDAQ:IMMU) stock went on a downward path that fall over -2.30% on Wednesday, amounting to a one-week price decrease of more than -3.88%. Over the last 12 months, IMMU stock rose by 8.60%. The one-year IMMU stock forecast points to a potential downside of -0.37, with the average price target set at $26.82 per share. The average equity rating for IMMU stock is currently 1.90, trading closer to a bullish pattern in the stock market.
The market cap for IMMU stock reached $4.18 billion, with 213.41 million shares outstanding and 197.55 million shares in the current float. Compared to the average trading volume of 2.23M shares, IMMU reached a trading volume of 1528856 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Immunomedics Inc. (IMMU)?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for IMMU shares is $26.82 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on IMMU stock is a recommendation set at 1.90. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Immunomedics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 27, 2019. While these analysts kept the previous recommendation, BofA/Merrill raised their target price to Buy. The new note on the price target was released on December 20, 2019, representing the official price target for Immunomedics Inc. stock. Previously, the target price had yet another drop from $28 to $26, while H.C. Wainwright kept a Buy rating on IMMU stock.
The Average True Range (ATR) for Immunomedics Inc. is set at 0.98. The Price to Book ratio for the last quarter was 150.54, with the Price to Cash per share for the same quarter was set at 1.73.
How has IMMU stock performed recently?
Immunomedics Inc. (IMMU) fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.88. With this latest performance, IMMU shares dropped by -5.32% in over the last four-week period, additionally plugging by 30.55% over the last 6 months – not to mention a rise of 8.60% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for IMMU stock in for the last two-week period is set at 47.55, with the RSI for the last a single of trading hit 43.08, and the three-weeks RSI is set at 50.26 for Immunomedics Inc. (IMMU). The present Moving Average for the last 50 days of trading for this stock 19.32, while it was recorded at 19.71 for the last single week of trading, and 16.00 for the last 200 days.
Immunomedics Inc. (IMMU): Deeper insight into the fundamentals
Return on Total Capital for IMMU is now -92.79, given the latest momentum, and Return on Invested Capital for the company is -100.68. Return on Equity for this stock declined to -151.56, with Return on Assets sitting at -45.66. When it comes to the capital structure of this company, Immunomedics Inc. (IMMU) has a Total Debt to Total Equity ratio set at 2.64. Additionally, IMMU Total Debt to Total Capital is recorded at 2.58, with Total Debt to Total Assets ending up at 1.34. Long-Term Debt to Equity for the company is recorded at 2.64, with the Long-Term Debt to Total Capital now at 2.58.
Reflecting on the efficiency of the workforce at the company, Immunomedics Inc. (IMMU) managed to generate an average of -$455,688 per employee. Current Ratio set at 6.50.
Earnings analysis for Immunomedics Inc. (IMMU)
With the latest financial reports released by the company, Immunomedics Inc. posted -0.5/share EPS, while the average EPS was predicted by analysts to be reported at -0.34/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -47.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for IMMU.
Insider trade positions for Immunomedics Inc. (IMMU)
There are presently around $3,230 million, or 79.20% of IMMU stock, in the hands of institutional investors. The top three institutional holders of IMMU stocks are: AVORO CAPITAL ADVISORS LLC with ownership of 21,000,000, which is approximately 0% of the company’s market cap and around 4.05% of the total institutional ownership; VANGUARD GROUP INC, holding 15,168,878 shares of the stock with an approximate value of $303.83 million in IMMU stocks shares; and BLACKROCK INC., currently with $285.15 million in IMMU stock with ownership of nearly 3.169% of the company’s market capitalization.
Positions in Immunomedics Inc. stocks held by institutional investors increased at the end of October and at the time of the October reporting period, where 115 institutional holders increased their position in Immunomedics Inc. (NASDAQ:IMMU) by around 9,506,163 shares. Additionally, 85 investors decreased positions by around 18,797,908 shares, while 36 investors held positions by with 132,978,956 shares. The mentioned changes placed institutional holdings at 161,283,027 shares, according to the latest SEC report filing. IMMU stock had 34 new institutional investments in for a total of 1,639,635 shares, while 24 institutional investors sold positions of 2,879,638 shares during the same period.